期刊文献+

鼻咽癌组织中EphA2的表达变化及其意义 被引量:6

The expression and its potentially clinical significance of EphA2 in nasopharyngeal carcinoma
原文传递
导出
摘要 目的:探讨鼻咽癌(NPC)组织中EphA2的表达情况及其与肿瘤发生、发展、侵袭、转移、新生血管生成和预后的相关性。方法:常规免疫组织化学技术检测61例NPC和20例鼻咽部慢性炎症组织中EphA2的表达情况,并分析EphA2的表达与NPC临床病理特征和微血管密度之间的关系。结果:NPC组织EphA2阳性表达率显著高于鼻咽慢性炎症组织(P<0.01)。EphA2阳性表达与NPC临床分期、颈淋巴结和远处转移、5年生存率等临床病理特征有关(P<0.05)。NPC组织中EphA2阳性表达者的微血管密度值显著高于阴性者(P<0.01)。结论:EphA2可能参与NPC的发生、发展、侵袭及转移,促进NPC的新生血管生成,与预后呈负相关。 Objective: To observe the expression of EphA2,and investigate its correlation with the development,progression,invasion,metastasis,angiogenesis and prognosis in nasopharyngeal carcinoma(NPC). Method: Immunohistochemical staining was used to determine the expression level of EphA2 protein in 61 cases NPC and 20 cases chronic nasopharyngitis samples.The clinically pathological data and results of follow-up were collected.Microvessel density(MVD) was also measured by immunohistochemical staining method with CD34 in NPC. Result: The positive rate of EphA2 protein staining in NPC was 60.66%(37/61),while that in nasopharyngitis samples was 10.0%(2/20).The positive rates of EphA2 protein in NPC were 27.27%(3/11) in stage Ⅰ,56.25%(9/16) in stage Ⅱ,68.19%(15/22) in stage Ⅲ,and 83.33%(10/12) in stage Ⅳ.The positive expressions of EphA2 in T1+T2 and T3+T4 with neck lymph node and distant metastasis were 58.33%(7/12) and 88.89%(16/18) respectively,while those in T1+T2 and T3+T4 without metastasis were 31.25%(5/16) and 50.00%(6/12) respectively.The cumulative survival of patients in the EphA2 positive group at 5 years was only 0.324(12/37),while 0.500(12/24) in the EphA2 negative group.The positive expression of EphA2 protein was correlated with the clinical stage,the neck lymph node metastasis and distant metastasis,and prognosis of NPC,respectively(P0.05).MVD in EphA2 protein positive group(45.32±4.91) was significantly higher than that in EphA2 protein negative group(28.69±3.99,P0.01). Conclusion: EphA2 may play an important role in the development and progression of NPC.It is closely associated with the invasion,metastasis,angiogenesis and prognosis of NPC.
出处 《临床耳鼻咽喉头颈外科杂志》 CAS CSCD 北大核心 2011年第18期827-829,833,共4页 Journal of Clinical Otorhinolaryngology Head And Neck Surgery
基金 无锡市科技局社会发展计划基金项目(No:CSE01012) 南京医科大学科技发展基金项目(No:07NMUM057)
关键词 鼻咽肿瘤 EPHA2 转移 血管生成 预后 nasopharyngeal neoplasms EphA2 metastasis angiogenesis prognosis
  • 相关文献

参考文献2

二级参考文献3

共引文献20

同被引文献66

  • 1罗清琼,陈万涛,胡水清,陈福祥.口腔鳞状细胞癌细胞TLR3表达及其配体poly(I:C)的诱导凋亡作用[J].上海交通大学学报(医学版),2011,31(1):5-8. 被引量:5
  • 2刘亚敏,孙江川,常漱芳.卵巢癌的化疗进展[J].重庆医学,2006,35(20):1903-1905. 被引量:6
  • 3Fayette J, Montella A, Chabaud S, et al. Paclitaxel is effec- tive in relapsed head and neck squamous cell carcinoma: a ret- rospective study of 66 patients at a single institution [ J ]. Anti- cancer Drugs, 2010, 21 (5): 553-558.
  • 4Holleman A, Chung I, Olsen RR, et al. miR-135a contrib- utes to paclitaxel resistance in tumor cells both in vitro and in vivo [J]. Oncogene, 2011, 30(43): 4386 -4398.
  • 5Ireton RC, Chen J. EphA2 receptor tyrosine kinase as a prom- ising target for cancer therapeutics [ J ]. Curt Cancer Drug Tar- gets, 2005, 5(3): 149 -157.
  • 6Landen CN, Merritt WM, Mangala LS, et al. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer[J]. Cancer Biol Ther, 2006, 5 (12) : 1708 - 1713.
  • 7Landen CN, Jr, Lu C, Han LY, et al. Efficacy and antivas- cular effects of EphA2 reduction with an agonistic antibody in o- varian cancer[J]. J Natl Cancer Inst, 2006, 98 (21): 1558 - 1570.
  • 8Kavallaris M. Mierotubules and resistance to tubulin-binding a- gents[J]. Nat Rev Cancer, 2010, 10(3) : 194 -204.
  • 9Liu Y, Zhang X, Qiu Y, et al. Clinical significance of E- phA2 expression in squamous-eell carcinoma of the head and neck[J]. J Cancer Res Clin Oneol, 2011, 137(5): 761 -769.
  • 10Liu Y, Yu C, Qiu Y, et al. Downregulation of EphA2 ex- pression suppresses the growth and metastasis in squamous-cell carcinoma of the head and neck in vitro and in vivo [ J ] . J Cancer Res Clin Oncol, 2012, 138(2): 195-202.

引证文献6

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部